. 2020 Jun 24;32(2):176–187.e4. doi: 10.1016/j.cmet.2020.06.015

Table 4.

Incidence Rate Ratios and Hazard Ratios for Secondary Outcomes and CK and Transaminase Elevation in Statin Group versus Non-statin Group and Statin+ACEi/ARB versus Statin+nonACEi/ARB after PSM

	Statin versus Non-statin					Statin+ACEi/ARB versus Statin+nonACEi/ARB
	IR	IRR (95% CI)	p Value^a	aHR^b (95% CI)	p Value^c	IR	IRR (95% CI)	p Value^a	aHR^d (95% CI)	p Value^c
Secondary Outcome

Invasive mechanical ventilation	0.11 versus 0.22	0.50 (0.33–0.76)	0.001	0.51 (0.34–0.78)	0.002	0.13 versus 0.15	0.85 (0.31–2.35)	0.755	1.11 (0.35–3.51)	0.854
ICU admission	0.29 versus 0.40	0.71 (0.55–0.93)	0.012	0.80 (0.62–1.05)	0.110	0.38 versus 0.47	0.82 (0.46–1.46)	0.494	0.78 (0.42–1.45)	0.427
ARDS	0.65 versus 0.81	0.80 (0.67–0.96)	0.016	0.88 (0.73–1.05)	0.159	0.64 versus 1.13	0.57 (0.37−0.86)	0.007	0.59 (0.37–0.92)	0.020
Septic shock	0.12 versus 0.13	0.92 (0.60–1.39)	0.684	0.93 (0.61–1.43)	0.744	0.11 versus 0.24	0.45 (0.17–1.18)	0.096	0.35 (0.12–1.07)	0.065
Acute liver injury	0.30 versus 0.28	1.06 (0.81–1.39)	0.653	1.17 (0.89–1.54)	0.253	0.27 versus 0.43	0.63 (0.33–1.22)	0.167	0.85 (0.42–1.74)	0.657
Acute kidney injury	0.13 versus 0.17	0.78 (0.53–1.16)	0.217	0.86 (0.58–1.28)	0.454	0.13 versus 0.23	0.57 (0.22−1.44)	0.227	0.57 (0.21–1.55)	0.268
Acute cardiac injury	0.51 versus 0.49	1.03 (0.84–1.26)	0.793	1.22 (0.99–1.50)	0.063	0.60 versus 1.05	0.57 (0.37–0.88)	0.010	0.61 (0.38–0.97)	0.038

CK and Transaminase Elevation

CK > ULN	0.40 versus 0.46	0.87 (0.69–1.09)	0.219	0.98 (0.78–1.24)	0.896	0.42 versus 0.53	0.80 (0.46–1.39)	0.424	0.91 (0.51–1.64)	0.765
ALT > 3ULN	0.23 versus 0.23	1.00 (0.74–1.36)	0.983	1.10 (0.81–1.49)	0.554	0.16 versus 0.41	0.40 (0.18–0.86)	0.016	0.60 (0.26–1.37)	0.223

IR (100-person-day), incidence rate; IRR, incidence rate ratio; aHR, adjusted hazard ratio; CI, confidence interval; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; CK, creatine kinase; ALT, alanine transaminase; ULN, the upper limit of normal.

p values were calculated by R package “fmsb”; the significant probability of the result of null-hypothesis testing.

Adjusted HR was calculated based on mixed-effect Cox model with adjustment of age, gender, and SpO2 on admission.

p values were calculated based on mixed-effect Cox model.

Adjusted HR was calculated based on mixed-effect Cox model with adjustment of age, gender, coronary heart disease, and incidence of increased CRP, D-dimer, and LDL-c on admission.